公开(公告)号：US20240102086A1

公开(公告)日：2024-03-28

申请号：US18370566

申请日：2023-09-20

Applicant: Bio-Rad Laboratories, Inc.

Inventor： Séverine MARGERIDON ,  Monica HERRERA ,  Richard DANNEBAUM ,  Nyaradzo DZVOVA ,  Raymond-John ABAYAN ,  Darren R. LINK

IPC: C12Q1/6853

CPC classification number: C12Q1/6853

Abstract: Methods and compositions comprising primers and probes to detect nucleic acids are provided. The probes comprise a ribonucleotide that can be cleaved by an RNase H2 enzyme when the probe is annealed to a reverse complement of a universal sequence that is introduced to a target nucleic acid, for example via amplification.

公开(公告)号：US20220119896A1

公开(公告)日：2022-04-21

申请号：US17507472

申请日：2021-10-21

Applicant: Bio-Rad Laboratories, Inc.

Inventor： Monica HERRERA ,  Josh SHINOFF

IPC: C12Q1/70 ,  C12Q1/689 ,  C12Q1/6895

Abstract: Methods of concentrating RNA from wastewater and quantifying the RNA by digital amplification are provided.

公开(公告)号：US20220259680A1

公开(公告)日：2022-08-18

申请号：US17670811

申请日：2022-02-14

Applicant: Bio-Rad Laboratories, Inc. ,  Biodesix, Inc.

Inventor： Dianna MAAR ,  Monica HERRERA ,  George KARLIN-NEUMANN ,  Josh SHINOFF ,  Audrey AUDETAT ,  Scott HUTTON ,  Hestia MELLERT ,  Leisa JACKSON ,  Gary PESTANO

IPC: C12Q1/6888

Abstract: Methods and compositions for characterizing a biological sample (e.g., comprising an infectious agent) from a subject are provided. Methods can include detecting linkage of nucleic acids that are linked in a viable cell or organism but that become degraded and thus unlinked in inviable cells or organisms and then characterizing the subject based on the quantity of linked and unlinked sequences.

公开(公告)号：US20240084374A1

公开(公告)日：2024-03-14

申请号：US18465321

申请日：2023-09-12

Applicant: Bio-Rad Laboratories, Inc.

Inventor： Chenyu LI ,  Olga MIKHAYLICHENKO ,  Nathan HENDEL ,  Anthony HENRIQUEZ ,  Richard DANNEBAUM ,  Monica HERRERA ,  Eric HALL ,  Séverine MARGERIDON ,  Thea RIEL

IPC: C12Q1/686

CPC classification number: C12Q1/686 ,  C12Q2600/154

Abstract: The digital amplification methods and kits provide the ability to estimate the fetal fraction of cell-free DNA (cfDNA) in a maternal sample, e.g., plasma or serum, by analysis of target sites that are differentially methylated in fetal and maternal cfDNA.